NGM

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the second of four virtual R&D events on Wednesday, April 27, 2022, from 11:00 am – 12:30 pm ET. This four-part series of virtual webcasts, titled the “Explorer Series”, will highlight the company’s work as explorers on the frontier of life-changing science.

The second event will focus on NGM Bio’s myeloid reprogramming programs targeting stromal checkpoints: NGM831, an ILT3 antagonist antibody product candidate, and NGM438, a LAIR1 antagonist antibody product candidate. ILT3 and LAIR1 are members of the LILR family of receptors, which may play a central role in establishing an immune-suppressive state in the tumor microenvironment. NGM831 and NGM438 are engineered to target ILT3 and LAIR1, respectively, with the goal of releasing myeloid checkpoints and reprogramming myeloid cells to enhance anti-tumor immunity. The program will feature presentations from David Woodhouse, Ph.D., NGM Bio’s Chief Executive Officer, Dr. Don Gibbons, M.D., Ph.D. at the MD Anderson Cancer Center where he is the Director of the Thoracic - Head and Neck Medical Oncology Translational Genetic Models Laboratory and Co-Leader of the Lung Cancer Moon Shot Program and multiple members of NGM Bio’s research and development team.

Future sessions will focus on NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, and NGM621, an anti-complement C3 antibody product candidate. Both sessions will feature members from NGM Bio’s management and scientific team as well as leading industry physicians and scientists.

A live webcast of the presentation will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of the webcast will be archived on NGM Bio’s site for one year following the event.

About NGM Bio

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has seven programs in active development, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Visit us at www.ngmbio.com for more information.

Abbreviations (in Alphabetical Order)

ILT2=Immunoglobin-Like Transcript 2; ILT3=Immunoglobin-Like Transcript 3; ILT4=Immunoglobin-Like Transcript 4; LAIR1=Leukocyte-Associated Immunoglobulin-Like Receptor 1; LILR= Leukocyte Immunoglobulin-Like Receptor [ILT2 = LILRB1, ILT3=LILRB4, ILT4=LILRB2]

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will,” “may,” “engineered to,” “goal,” “aspire,” “aim” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to NGM Bio’s product candidates, including the potential role of ILT3 and LAIR1 in establishing an immune-suppressive state in the tumor microenvironment and the possibility that releasing myeloid checkpoints and reprogramming myeloid cells can enhance anti-tumor immunity, and other statements that are not historical fact. Because such statements deal with future events and are based on NGM Bio’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of NGM Bio could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, as well as the risks that NGM Bio’s product candidates may otherwise not be tolerable and effective treatments in their planned indications, and other risks and uncertainties affecting NGM Bio and its development programs, including those discussed in the section titled “Risk Factors” in NGM Bio’s annual report on Form 10-K for the quarter and year ended December 31, 2021 filed with the United States Securities and Exchange Commission (SEC) on March 1, 2022 and future filings and reports that NGM Bio makes from time to time with the SEC. Except as required by law, NGM Bio assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Investor Contact:Brian Schoelkopfir@ngmbio.com

Media Contact:media@ngmbio.com